gilead yeztugo - Search News

News

FDA approves Yeztugo

FDA approves Yeztugo: Gilead's new twice-yearly HIV prevention injection

He affirmed that the new drug "could take the epidemic to the history books," according to Mother Jones.Yeztugo, based on the molecule lenacapavir, offers a more effective and less invasive prevention method,

Benzinga · 2d

FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over its $28K annual price.

PharmExec · 2d

FDA Approves Gilead’s Yeztugo as First Twice-Yearly Injection for HIV Pre-Exposure Prophylaxis

Approval of first twice-yearly HIV pre-exposure prophylaxis was based on results from the Phase III PURPOSE 1 and PURPOSE 2 trials, which show that ≥99.9% of patients treated with Yeztugo remained HIV-negative.

Stocktwits on MSN2d

Gilead Earns Analyst Praise As FDA Clears Yeztugo For Biannual HIV Prevention

Gilead Sciences garnered investor and analyst focus after the U.S. FDA approval of Yeztugo, or lenacapavir, the company’s ...

Gilead Sciences (NasdaqGS:GILD) Gains FDA Approval For Yeztugo As PrEP HIV Option

Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first ...

Fierce Pharma3d

FDA signs off on Gilead's landmark long-acting PrEP med, signaling new era in HIV prevention

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...

NBC News3d

FDA approves powerful HIV drug that nearly eliminated spread in clinical trials

Among gay and bisexual men and transgender people, the Yeztugo group had an 89% lower HIV rate than a group taking Truvada and a 96% lower rate than Gilead estimated would have been expected ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results